Aescin showed antiproliferative effects with a noticeable reduction in prostate weight through mitigating the expression of TGF-β1, and therefore, repressing the testosterone-induced PCNA elevation in BPH rat prostates. This evidence concerns the gene TGFB1 and benign prostatic hyperplasia.